A brief review of donanemab (Kisunla®) for Alzheimer’s disease

This article was published on August 14, 2024. In 2024, the US Food and Drug Administration approved another medication for the treatment of Alzheimer’s disease in its early stages. What is donanemab (Kisunla®)? Developed by Eli Lilly and Company, donanemab (Kisunla®) is a monoclonal antibody against amyloid beta. What is its FDA indication?  Donanemab has…